Lilly's blockbuster Mounjaro boosts third quarter results, supply issues persist
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Citi continue to see upside to Eli Lilly & Co.'s (LLY) 'already rich' valuation
November 2, 2023 11:11 AM EDTCiti analyst Andrew Baum said in a note Thursday that the Mounjaro beat for Eli Lilly & Co. (NYSE: LLY) goes on after the companys solid third-quarter results, which were boosted by the drug.
Baum reiterated a Buy rating and $675 price... More
